【召集人專欄】<藥物安全系列二> Efficacy versus Safety, which comes first? (Liang-Ni Wu)

Further to my Introduction to Drug Safety Series posted in August 2016, I did not expect to a hot discussion over this not-so-popular topic. Indeed, there were only two comments posted - but I was surprised, and quite amazed to read these comments...

在〈【召集人專欄】<藥物安全系列二> Efficacy versus Safety, which comes first? (Liang-Ni Wu)〉中留言功能已關閉

【召集人專欄】淺談國際專利申請制度PCT

由於專利權為屬地主義權利,專利權僅在核准專利的該國家/地區有效,當某發明欲取得多國專利保護,就必須在這些國家分別提出專利申請,經審查核准後始能獲得專利。而各國的專利主管機關在接受該發明之申請案後,亦須分別進行檢索、審查。

在〈【召集人專欄】淺談國際專利申請制度PCT〉中留言功能已關閉